Hey Bate, I understand and have your same concerns, but hopefully, this goes down to .01 cents per share soon, so we can greatly average down again.
I know we all want Fluticare ANDA approval and that we've been waiting a long time for it.
It seems like there is always a catch though, because Innovus doesn't have enough cash to market and sell Fluticare worldwide, so there would probably have to be some sort of a sad, stock offering to raise some capital.
In the short term, the Fluticare ANDA approval could backfire with a negative impact.
I'm sure that Fluticare ANDA approval would make Innovus a better buyout target and would in the long term increase sales.
